An introduction to the official launch time of Elacetrant in the country and related approval progress

Elacestrant (Elacestrant) is an innovative selective estrogen receptor degrader (SERD), mainly used to treat It is suitable for the treatment of patients with estrogen receptor-positive (ER+) and HER2-negative breast cancer. It is especially suitable for patients with advanced breast cancer who have received endocrine therapy and are resistant to endocrine therapy. By specifically degrading estrogen receptors, elastran can inhibit tumor cell proliferation and provide a new treatment option for patients who are resistant to endocrine therapy.

As of2025, elastran has not been officially launched in mainland China, so domestic patients are temporarily unable to purchase the drug through hospitals or pharmacies. At present, the drug's marketing application in China has not yet been approved by the National Medical Products Administration (NMPA), and there is no public information showing that it has entered the clinical trial stage. The time to market is uncertain, and patients can only obtain the latest information by paying attention to clinical trials or future official marketing announcements.

On the international market, elastran has been approved and marketed in Europe. The price of the original medicine is about more than 30,000 yuan per box, which is relatively high. In order to reduce the cost of medication, some countries such as Laos have launched generic versions of drugs. The price is about more than 2,000 yuan, and the drug ingredients are basically the same as the original drugs, providing a viable option for patients with greater financial burdens. However, international drug purchases need to follow local laws, regulations and formal channels to ensure drug quality and drug safety.

Overall, elastran is still waiting to be launched in China, and it will be difficult for domestic patients to obtain it in the short term. As the drug approval process advances, it is expected to enter the domestic market in the future and provide new treatment options for patients with breast cancer who are resistant to endocrine therapy. Prior to this, patients should maintain communication with their attending doctors, pay attention to international clinical progress and formal drug purchase channels, and scientifically plan treatment plans.

Reference link:https://www.drugs.com